MedTrace Logo

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy

NCT03911219 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 154

Last updated 2021-10-05

No results posted yet for this study

Summary

The current study is aimed to test the benefit of a web-based application tool in NSCLC, SCLC and TNBC patients during the recently approved first-line treatment strategy with atezolizumab in combination with chemotherapy.

Conditions

  • Stage IV Non-small Cell Lung Cancer
  • Extensive-stage Small Cell Lung Cancer
  • Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC

Interventions

OTHER

eHealth system support for symptom management via CANKADO

Regular use of eHealth support system CANKADO by the patient: symptom self-reporting triggering alerts to the patient; in addition to standard of care symptom management.

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Manfred Welslau, Dr. · MVZ am Klinikum Aschaffenburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-10
Primary Completion
2021-07-01
Completion
2021-07-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03911219 on ClinicalTrials.gov